Background: the development of an objective and comprehensive drug-based index of physical function for older adults has the potential to more accurately predict fall risk. Design: the index was developed using 862 adults (ages 57-85) from the National Social Life, Health, and Aging Project (NSHAP) Wave 1 study. The index was evaluated in 70 adults (ages 51-88) from a rehabilitation study of dizziness and balance. Methods: the prevalence among 601 drugs for 1,694 side effects was used with fall history to determine the magnitude of each side effect's contribution towards physical function. This information was used to calculate a Medication-based Index of Physical function (MedIP) score for each individual based on his or her medication profile. The MedIP was compared to the timed up and go (TUG) test as well as drug counts using receiver operating characteristic (ROC) analysis. The associations between various indices of physical function and MedIP were calculated. Results: within the NSHAP data set, the MedIP was better than drug counts or TUG at predicting falls based on ROC analysis. Using scores above and below the cutpoint, the MedIP was a significant predictor of falls (OR = 2.61 [95% CI 1.83, 3.64]; P < 0.001). Using an external data set, it was shown that the MedIP was significantly correlated with fall number (P = 0.044), composite physical function (P = 0.026) and preferred gait speed (P = 0.043). Conclusion: the MedIP has the potential to become a useful tool in the healthcare and fall prevention of older individuals.
Introduction
In the USA, falls are a significant and costly health concern among older individuals. Each year, 2.5 million people, 65 and older are treated in emergency departments for falls, resulting in over 700,000 hospitalisations [1] . Falls are among the 20 most expensive medical conditions, with an average hospital cost for a fall-related injury of $35,000, leading to an estimated burden of $34 billion dollars annually on the healthcare system [2, 3] . Falls in older adults are a multifactorial clinical problem composed of intrinsic and extrinsic factors, some of which are modifiable and others are not. Intrinsic fall risk factors such as older age or previous fall history are not modifiable [4] . One potentially modifiable extrinsic fall risk factor is a patient's medication profile. This factor in and of itself is also multifaceted. Drug-associated fall risk may be dependent on drug class and/or the number of drugs a patient takes. Drug classes associated with fall risk include but are not limited to centrally acting drugs, cardiovascular drugs, diuretics and hypoglycaemia drugs [5] [6] [7] [8] . Unfortunately, the contribution attributed to specific drugs and drug classes associated with fall risk vary by investigation. Part of the variation may be cohort related, but another part of the variation may be related to polypharmacy [9, 10] .
The need, therefore, to assess drug-related fall risk has produced numerous solutions. These solutions generally fall into one of two major categories. The first category includes general prescriptive guidelines assessing clinical benefit of drugs compared to their overall risk. These guidelines include Beer's Criteria, Screening Tool of Alert Doctors to the Right Treatment and Screening Tool of Older Person's potentially inappropriate Prescriptions, and are designed to inform prescribers of known side effects [11, 12] . In contrast, the second category includes attempts to quantify side effects of drugs. Those attempting to quantify drug-associated fall risk include the Anticholinergic Risk Scale (ARS), Anticholinergic Cognitive Burden (ACB) and Drug Burden Index (DBI) [13] [14] [15] [16] [17] . The ARS and ACB focus on the central nervous anticholinergic side effects of drugs on cognition and function. The DBI, whose calculation requires dosage information, also examines the effects of drugs on cognition and function, but does so by examining both anticholinergic and sedative side effects. Although both central anticholinergic and sedative drugs are associated with fall risk, there are additional drugs with different mechanisms of action that increase fall risk and are not captured by these indices. Additionally, these systems were developed based on established concepts of drug-associated fall risk, and may be subject to anchoring bias by pre-existing paradigms of drug action.
Although there are multiple physiological mechanisms by which these drugs may increase fall risk, previously described drug-associated fall risk indices are based only on subsets of known drug-side effects that are presumed to increase fall risk. Such bias may miss additional side effects that can increase fall risk. We hypothesise that a comprehensive Medication-based Index of Physical function (MedIP) can be generated using fall history to optimise the contribution of each side effect to physical function. The following study describes the creation of the MedIP and its evaluation as a measure of physical function and predictor of falls based solely on a patient's medication profile.
Methods

Data acquisition
To develop the MedIP, data pertaining to individuals, their medication profiles, co-morbidities, functional testing and fall history was obtained from the Wave 1 data set from the National Social Life, Health, and Aging Project (NSHAP) [18] . The NSHAP study was designed to collect data on the health and social factors of older, community-dwelling individuals in order to give health providers and policy makers information and insights. The Wave 1 data used in the present study were collected in 2005 and 2006 during face-toface interviews in the respondents' homes. These data were acquired for secondary analysis from the Inter-University Consortium for Political and Social Research with help from Dr L. Phillip Schumm and Arun Mathur. Of the 3,005 individuals interviewed in this data set, 569 were excluded due to an absence of reported medications, 1,344 were excluded due to an incomplete Timed Up and Go (TUG) measurement, 25 were excluded for the use of canes or walkers and 204 were excluded because they did not respond to a question regarding fall history. The remaining 862 patients were included to calculate the MedIP, and subsequent comparisons. External evaluation of the MedIP was conducted by a secondary analysis of an external data set that was collected separately for a rehabilitation study of dizziness and balance. This study was designed to determine what exercises are best for patients (50 years and older) with dizziness that has lasted at least 1 month. Baseline demographic and health history information used in the present study were reported by the participants at their homes via self-report questionnaire and collected between 2013 and 2016. The physical performance data used in this study were collected in a Gait/Balance laboratory at the Mountain Home VA Medical Center by a trained research physical therapist and audiologist. A table comparing the demographic characteristics of the two data sets can be found in the Supplementary data, Appendix, are available in Age and Ageing online.
Data pertaining to drugs, their associated side effects, and the prevalence of those side effects was obtained from the Side Effect Resource (SIDER) 2.0 data set [19] . Of the 996 drugs contained within the SIDER 2.0 database, 601 overlapped with drugs reported in the Wave 1 NSHAP data set. As the SIDER database aggregates information from a variety of documents, all of these drugs contained upper and lower bounds of side effect frequency information from multiple primary sources. To consolidate the frequency information into a single value for each drug-side effect pair, only MedDRA (Medical Dictionary for Regulatory Activities) preferred terms were considered, and an average of the upper frequency bounds from all sources was calculated for each pair.
Score calculation and optimisation
The MedIP was calculated using elementary matrix operations. The algebraic description of the MedIP calculation can be found in the Supplementary data, Appendix, are available at Age and Ageing online. In brief, the MedIP score for each patient is based on the sum of the drugs an individual is taking, weighted by the side effects for each drug, and the contribution of those side effects towards fall risk. For example, if an individual was taking drugs A and B, where the frequency of side effects C and D for drug A were 25% and 50%, respectively, the frequency of side effects C and D for drug B were 75% and 100%, respectively, and the contribution of side effects C and D towards fall risk were 2 and 4, respectively, then the patient's MedIP score would be: C. D. Hall et al.
To optimise the MedIP, the point-biserial correlation coefficient was calculated between the MedIP and response to the question, 'In the past 12 months, have you fallen?'. Using MATLAB (version R2015b, MathWorks) and its corresponding Optimisation toolbox, the point-biserial correlation coefficient between the MedIP and fall history was maximised by iteratively changing the weightings of each side effect towards fall risk (solver: fminunc-unconstrained nonlinear minimisation of the additive inverse of the point-biserial correlation, algorithm: trust region) [20] . Scores for individual drugs reported in Table 1 were calculated by summing the products of side effect frequencies and fall risk weights.
Score evaluation
The MedIP was corroborated using an external data set that included patient measurements of fall history, the Functional Comorbidity Index [21] , composite physical function [22] , Activities-specific Balance Confidence (ABC) scale [23] , Mini-Mental Status Exam [24] and preferred gait speed [25] .
Statistical analysis
For the NSHAP data set, receiver operating characteristic (ROC) curves and their corresponding areas (AUC) were calculated for MedIP, drug counts and TUG with fall history as the binary outcome using IBM SPSS Statistics version 23. Statistical comparison of the AUCs was performed using SAS for Windows version 9.4 and the non-parametric approach of DeLong et al. [26] . Cutpoints for MedIP, TUG and drug count were determined by selecting the points along each curve that were nearest to (0, 1), representing 100% sensitivity and 100% specificity. Odds ratios and correlations were calculated using Prism 6 for Mac OS X (GraphPad).
For the external data set, correlations between the MedIP and fall number, Functional Comorbidity Index, composite physical function, ABC scale, Mini-Mental Status Exam and preferred gait speed were conducted using Spearman's correlation due to the non-normal distribution of several variables.
Results
Score calculation and optimisation
Using the NSHAP data set, the MedIP was found to be significantly better than both drug count (χ 2 , P = 0.0082) and TUG (χ 2 , P = 0.0288) at discriminating between fallers and non-fallers ( Figure 1A) . By selecting cutpoints that simultaneously maximised specificity and sensitivity, it was shown that the MedIP (cutpoint = 2,764) had a notably higher odds ratio (OR = 2.612, 95% CI: 1.873-3.642) for predicting falls than either drug count (cutpoint = 5.5, OR = 1.552, 95% CI: 1.112-2.149) or TUG (cutpoint = 12.5, OR = 1.502, 95% CI: 1.085-2.073) (odds ratios refer to values above or below cutpoints, Figure 1B ).
Score evaluation
To further evaluate the MedIP as an indicator of physical function, an external data set was used containing a separate pool of participants and different metrics of physical function. The MedIP score for these patients showed a moderate and statistically significant correlation with several different indices of physical function and comorbidity ( Table 2 ). The number of falls in the past 12 months had a significant positive correlation with the MedIP, whereas composite physical function and preferred gait speed had a significant negative correlation with the MedIP. The MiniMental State Examination (MMSE), ABC Scale, and Functional Comorbidity Index did not demonstrate a significant correlation to the MedIP.
Discussion
The MedIP represents a novel metric for assessing the physical function and comorbidity of a patient based on their medication profile. The development of the index was accomplished computationally to avoid any preconceived notions regarding the impact of certain side effects on physical function. As shown in Figure 1 , a higher degree of discrimination between fallers and non-fallers was achieved with the MedIP compared to either drug count or TUG. The MedIP was compared against drug count because it is an accepted clinical standard for drug-based impact on physical function. The MedIP was also compared to the TUG, as the TUG is a common functional test used clinically. The cutpoints derived from the ROC analysis and used to compute the odds ratios showed good agreement with the literature. The cutpoint for drug counts was in agreement with a systematic review which documented that most studies on polypharmacy found a large and significant fall risk among individuals taking five or more drugs [9] . The TUG cutpoint was similar to other studies using the TUG as a measure of physical function [27, 28] . Despite the unconventional calculation of the MedIP, the scores it produced were significantly correlated with more traditional measures of physical function. Using the external data set, the MedIP was found to be significantly correlated with number of self-reported falls, composite physical function and Preferred Gait Speed. The correlation with number of falls was positive, i.e. the higher an individual's MedIP, the more falls he or she is likely to endure. The correlations with composite physical function and Preferred Gait Speed were negative, indicating that the higher an individual's MedIP, the slower his or her gait, and the worse his or her physical function. Since the MedIP was derived using fall history, the high degree of correlation between the MedIP and physical function appears to corroborate the observations made in other studies regarding the inextricable connection between fall risk and physical function [29] . No significant correlation was found between the MedIP and MMSE, the ABC Scale, or the Functional Comorbidity Index. As the MMSE does not directly measure physical function, this result was unsurprising. The lack of significant correlation between the MedIP and the ABC scale may be due to the more subjective nature of the ABC compared to the other metrics. The Functional Comorbidity Index focuses on diagnosable illnesses and may not capture the various side effects caused by multiple medications. Given the small sample size of the external data set, further studies will be necessary to validate the MedIP using a larger more representative population.
The blinded development of the MedIP resulted in the identification of drugs with a negative or positive impact on fall risk that were not entirely compatible with existing pharmacological precepts. Previous studies have identified multiple drugs and even entire drug classes as agents capable of increasing the risk of falls [10, 11, 13, 14, 30] . Accordingly, half of the top 10 drugs identified by the MedIP as having a negative impact on physical function are also included on Beers' list [11] . However, among the top 10 drugs identified by the MedIP as having a positive impact on physical function were four that also appear on Beers' list. An accounting of each drug's pharmacological actions is beyond the scope of this discussion, but a putative mechanism has been identified based on a careful appraisal of drug pharmacology, target function and target expression (see Supplementary data, Appendix, available at Age and Ageing online). In short, the common mechanistic denominator among the drugs identified by the MedIP as being beneficial to physical function is that they increase glutamatergic transmission and/or decrease GABAergic, dopaminergic and adrenergic transmission, while the drugs identified by the MedIP as negatively affecting physical function tend to increase GABAergic, dopaminergic, and adrenergic transmission and/or decrease glutamatergic transmission.
The analysis presented above suggests a causal relationship between drugs and physical function. However, an equally compelling alternative hypothesis is that the drugs and side effects that have the largest impact on the MedIP are symptomatic of poor overall health status. Since a poor overall health status is usually indicative of decreased physical function, the MedIP could be simply an indicator of comorbidity. Another possibility is that patients receive much more counselling from their pharmacists on the drugs suggested by the MedIP as positively influencing physical function. As such, they are more aware of the risks of falling and thus take additional precautions to prevent falls. Regardless of the exact cause, this study demonstrates that the MedIP is significantly correlated with other canonical tests of physical function. Given that the medication profile of a patient is acquired as a matter of course during almost any healthcare intervention, the MedIP represents an opportunity to quickly screen patients and triage their needs with regards to physical function. Other basic information, such as age and sex, may be incorporated into the index in the future if they are found to improve the specificity and sensitivity of the index as a prognostic tool. As the MedIP is calculated computationally, it could be easily integrated into existing EMR platforms and serve as a first alert that a patient may need physical therapy to improve their mobility and quality of life. EMR integration is essential to making the MedIP accessible to all healthcare specialties. Because it does not require a functional test or necessitate that the patient answer a questionnaire, the MedIP has the potential to save precious time and resources. If incorporated into routine clinical use, the Drug-based Index of Physical function has the potential to impact the healthcare of millions of individuals.
Key points
• The Medication-based Index of Physical function (MedIP) was derived computationally using fall histories.
• The MedIP is significantly better than drug counts at predicting falls.
• The MedIP is significantly associated with indices of physical function.
Supplementary data
Supplementary data are available at Age and Ageing online.
